US Justice Department closes investigation into Cassava Sciences over Alzheimer drug research
The US Justice Department has ended its probe into Cassava Sciences over research misconduct. This follows the dismissal of a case against a former adviser.
Insights:
The U.S. Department of Justice has formally ended its investigation into Cassava Sciences, Inc. regarding allegations of research misconduct involving the company's experimental Alzheimer's drug, simufilam. The closure of the probe, announced on February 19, 2026, marks the completion of a federal inquiry in the US 
US that had scrutinized the development process of the pharmaceutical candidate.
US that had scrutinized the development process of the pharmaceutical candidate.
